Monday, 31 August 2026European Markets

AZERION Stock Over 10% Down So Far On Tuesday

Loading stream...

(VIANEWS) - Shares of AZERION (AEX-Index: AZRN.AS) fell by a staggering 10.61% to €2.78 at 11:07 EST on Tuesday, after five successive sessions in a row of gains. AEX-Index is falling 0.08% to €763.51, following the last session's downward trend. This seems, up to now, a somewhat down trend exchanging session today.

AZERION's last close was €3.11, 66.2% under its 52-week high of €9.20.

About AZERION

Azerion Group N.V. operates a digital entertainment and media platform worldwide. Its integrated platform offers technology solutions to automate the purchase and sale of digital advertising inventory for advertisers, publishers, and game creators, as well as to develop, publish, distribute, and operate online social and casual games, and digital content. The company was founded in 2014 and is headquartered in Schiphol-Rijk, the Netherlands.

Earnings Per Share

As for profitability, AZERION has a trailing twelve months EPS of €-1.72.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -298.1%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AZERION's stock is considered to be oversold (<=20).

More news about AZERION (AZRN.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com